Ceftazidime/avibactam is a cephalosporin/beta-lactamase inhibitor, with excellent activity against KPC and OXA-48-like producing CRE and non-carbapenemase-producing CRE, and it is currently approved for use in patients ≥3 months for the treatment of complicated intra-abdominal infections, complicated UTIs, hospital-acquired pneumonia, and BSI associated with those conditions; it is also approved for treatment of infections caused by Gram negatives with limited treatment options [45]. The gene discussed is LACTB; the disease is bathing suit ichthyosis.